Corvus Pharmaceuticals, Inc. - 10-Q Filing
Corvus Pharmaceuticals filed its 10-Q for the quarter ended March 31, 2026, reporting $40.1 million in cash and cash equivalents as of March 31, 2026, compared to $4.6 million as of December 31, 2025. The company also disclosed activities related to a follow-on public offering on January 23, 2026, and an at-the-market offering managed by Jefferies LLC during the quarter.
Tickers: $CRVS